Assessing Metabolic State of 3D Tumor Models

Translational cancer research is increasingly incorporating 3D cell models like organoids, tumoroids and other patient-derived samples. Progression of a tumor and its response to therapy has been closely linked to metabolic reprogramming in cancer cells. Therefore, metabolism assays have become an important part of the tumor treatment response multifunctional profiling. This necessitates efficient workflows for timed supernatant sample collection to analyze the dynamics of metabolite secretion in response to treatment.

In this joint webinar by Protein Fluidics and Promega, scientists will show how 3D-optimized metabolite assays can be used with cell models to assess their metabolic state. An automated Pu·MA System workflow to capture dynamic metabolite secretion from patient-derived tumoroids will be featured. The speakers will also discuss technical aspects of assay optimization, including monitoring changes in metabolites upon timed drug treatments.